Category: Blog

Survodutide Safety Studies — Clinical Trial Insights

Phase 2 survodutide safety studies show GI events in 40–55% of patients, but 89% reach target dose. What the latest trials reveal about dual-agonist

Survodutide Long Term Studies — Efficacy Data & Safety

Clinical trials show survodutide maintains weight loss beyond 48 weeks with sustained metabolic improvements. Phase 3 data demonstrates durability with

Survodutide Comparative Studies — Evidence Review

Survodutide demonstrates dual GLP-1/glucagon receptor agonism with superior weight loss versus semaglutide in head-to-head trials — MASH outcomes remain

Survodutide Mechanism Studies — Dual Receptor Insights

Survodutide mechanism studies reveal dual GLP-1/glucagon receptor agonism driving 15.7% body weight reduction and metabolic improvements through hepatic

Mazdutide Study — Phase 3 Results and Clinical Insights

Mazdutide study data reveals dual GLP-1/glucagon receptor agonism delivers 20.6% mean weight loss in 48 weeks with significant metabolic improvements.

Top Mazdutide Studies — Clinical Trial Results & Data

Mazdutide demonstrates 20.2% weight reduction in phase 2 trials with dual GLP-1/glucagon receptor activation — clinical data reveals metabolic mechanisms

Mazdutide Animal Research — Mechanisms and Early Findings

Mazdutide animal research reveals potent dual GLP-1/glucagon agonism driving 30-40% body weight reduction in rodents — mechanisms, dosage findings, and

Mazdutide Dose Response Research — Clinical Findings

Mazdutide dose response research demonstrates 15–25% weight reduction at higher doses. Phase 2 trials reveal optimal titration schedules and metabolic

Mazdutide Long Term Studies — Clinical Evidence Review

Mazdutide long term studies show sustained weight reduction and metabolic benefits beyond 24 weeks, with dual GLP-1/glucagon receptor agonism driving

Mazdutide Safety Studies — Clinical Evidence Review

Phase 2/3 mazdutide trials show 12–24% weight loss with manageable GI side effects. Here’s what the clinical safety data reveals about this dual-agonist